Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients (Q44078454)

29 November 2017

Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients (English)

1 reference

29 November 2017

0 references

7

1 reference

29 November 2017

Flavio Nobili

1

0 references

author name string

Paolo Vitali

2

1 reference

29 November 2017

Michela Canfora

3

1 reference

29 November 2017

Nicola Girtler

4

1 reference

29 November 2017

Caterina De Leo

5

1 reference

29 November 2017

Giuliano Mariani

6

1 reference

29 November 2017

Guido Rodriguez

8

1 reference

29 November 2017

1 August 2002

1 reference

29 November 2017

Clinical Neurophysiology

1 reference

29 November 2017

113

1 reference

29 November 2017

8

1 reference

29 November 2017

1241-1248

1 reference

Correlations of topographical EEG features with clinical severity in mild and moderate dementia of Alzheimer type.

29 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

Cholinergic markers in elderly patients with early signs of Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

Donepezil: a review of its use in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

1 reference

7 January 2021

Comparing functional (PET) images: the assessment of significant change

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

Spatial registration and normalization of images

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

Cholinesterase inhibitors for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

Emission tomography contribution to clinical neurology

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

Cerebral blood flow and metabolic abnormalities in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

Treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

The cholinergic deficit in Alzheimer's disease: impact on cognition, behaviour and function.

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

Clinical brain radionuclide imaging studies

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

The ability of THA treatment to increase cortical alpha waves is related to apolipoprotein E genotype of Alzheimer disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

Quantitative Electroencephalography and Regional Cerebral Blood Flow: Discriminant Analysis between Alzheimer’s Patients and Healthy Controls

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

Hippocampal perfusion in mild Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

Cholinergic neural regulation of regional cerebral blood flow.

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET.

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

Changes in the rCBF images of patients with Alzheimer's disease receiving Donepezil therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

P300 in Alzheimer's disease: relationships to dementia severity and glucose metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

Docosahexaenoic acid (DHA) improves the age-related impairment of the coupling mechanism between neuronal activation and functional cerebral blood flow response: a PET study in conscious monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1388-2457%2802%2900110-4

7 January 2021

10.1016/S1388-2457(02)00110-4

Identifiers

DOI

1 reference

29 November 2017

1 reference